Table 1.

Profile of patients

Patient	Sex	Age	CD4+, cells/mm3	HIV-1 RNA*, copies/ml	Months on anti-viral therapy	Anti-HIV therapeutics received
1	M	50	361	246,700	64	AZT, ddl, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV, DLV
2	M	38	3	553,700	46	AZT, ddl, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV
3	M	44	108	42,610	39	AZT, ddl, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV
4	M	40	568	59,990	81	AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, APV, DLV
5	M	38	297	52,760	32	AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, APV
6	M	36	554	15,730	34	AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, APV
7	M	45	335	6,547	83	AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, RTV, APV

ddC, zalcitabine; d4T, stavudine; ABC, abacavir (1592U89); APV, amprenavir (VX-478/141W94); DLV, delavirdine; M, male. 

^*Serum levels of HIV RNA were determined by using a branched-DNA assay.